New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:34 EDTMRKMerck says Zontivity approved for reduction of thrombotic cardiovascular events
Merck announced that the U.S. FDA has approved ZONTIVITY for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or in patients with narrowing of leg arteries, called peripheral arterial disease. For patients with a history of heart attack or with PAD who had no history of stroke or transient ischemic attack, ZONTIVITY added to standard of care produced a significant 17% relative risk reduction over the three years of the study for the combined events of cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization. For the key secondary composite efficacy endpoint of CV death, MI and stroke alone, ZONTIVITY produced a significant 20% relative risk reduction in these patients. These results were driven by an 18% relative risk reduction in MI and a 33% relative risk reduction in first stroke.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent MRK news | >>
April 28, 2015
12:30 EDTMRKOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after crossing back and forth across the flat line during morning trading, much like Apple (AAPL) shares, which were searching for direction despite the company's report last night having topped expectations on several measures, including revenue, profits, iPhone unit sales and capital return plans. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rebounded 0.93% on a seasonally adjusted basis in February, versus expectations for it to be up 0.7% on a month-over-month basis. The Conference Board's consumer confidence index dropped 6.2 points to 95.2 in April, versus expectations for it to have risen to 102.2. The Richmond Fed manufacturing index rose to -3 in April, versus expectations for a reading of -2. COMPANY NEWS: Shares of Apple were little changed near noon after the company last night reported March quarter earnings and sales well above expectations and boosted its shares buyback program to $140B from $90B and quarterly dividend by 11% to 52c. FBR Capital called the quarter “Picasso-like,” while Brian White at Cantor Fitzgerald upped his price target on shares to $195. Less sanguine are analysts at Pacific Crest, Maxim and Deutsche Bank. Noted investor Carl Icahn said afterward that Apple is "still undervalued and misunderstood" and promised to put out another in-depth report on the company within two weeks... IBM (IBM) approved an 18% increase in its quarterly dividend to $1.30 per common share. MAJOR MOVERS: Among the notable gainers was Dow member Merck (MRK), which advanced 5% after its Q1 sales and EPS beat expectations. Two other big name, big revenue drugmakers slid after their earnings reports, as Bristol-Myers (BMY) declined 1% and Pfizer (PFE) fell 0.5%. Also lower following its earnings report was The Container Store (TCS), which declined about 16% after its results and outlook missed expectations. INDEXES: Near midday, the Dow was up 49.61, or 0.28%, to 18,087.58, the Nasdaq was up 9.87, or 0.2%, to 5,070.12, and the S&P 500 was up 3.98, or 0.19%, to 2,112.90.
10:00 EDTMRKMerck trades sharply higher after results, levels to watch
The stock is trading up over 5% to $60.17 following results. At that price the only resistance level of significance is at the 52-week high at $63.62. Support is at $59.73, the session low.
09:36 EDTMRKActive equity options trading on open
Subscribe for More Information
08:46 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:27 EDTMRKMerck HCV results appear inferior, says Bernstein
Subscribe for More Information
07:59 EDTMRKMerck HCV data supports NDA filing, says SunTrust
SunTrust believes that Merck's C-EDGE & C-SURFER efficacy data at EASL indicates that the company's HCV treatment is competitive with Gilead's (GILD) single pill dose and superior to AbbVie's (ABBV) Viekira Pak. The firm says the data supports Merck's imminent NDA filing with breakthrough designation, potentially enabling a 2H15 launch. It keeps a $72 price target and Buy rating on the shares.
07:03 EDTMRKMerck sees FY15 EPS $3.35-$3.48, consensus $3.37
Sees FY15 revenue $38.3B-$39.8B, consensus $39.2B.
07:02 EDTMRKMerck reports Q1 EPS 85c, consensus 74c
Subscribe for More Information
April 27, 2015
18:56 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
18:32 EDTMRKMerck announces publication of pivotal data from Zerbaxa Phase 3 clinical study
Subscribe for More Information
17:13 EDTMRKMerck announces Januvia study achieved primary endpoint
Merck announced that the trial evaluating cardiovascular outcomes with Sitagliptin, or TECOS, of Merck's DPP-4 inhibitor, Januvia, or sitagliptin, achieved its primary endpoint of non-inferiority for the composite cardiovascular endpoint. Among secondary endpoints, there was no increase in hospitalization for heart failure in the sitagliptin group versus placebo. The complete results of TECOS will be presented on June 8 at the Scientific Sessions of the American Diabetes Association. TECOS was an event-driven trial conducted in adults with type 2 diabetes and a history of cardiovascular disease. The study was designed to assess the CV safety of long-term treatment with Januvia as part of usual diabetes care compared with usual care without Januvia. The primary endpoint was the composite of time to the first of any of the following confirmed events: cardiovascular-related death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. TECOS enrolled 14,724 participants from 38 countries between December 2008 and July 2012. The median patient follow-up was approximately three years.
15:04 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
13:43 EDTMRKEarnings Watch: Merck shares lower by about 5.6% since last earnings report
Subscribe for More Information
09:37 EDTMRKBarclays healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
06:19 EDTMRKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
07:58 EDTMRKMerck May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
05:35 EDTMRKMerck Phase 3 C-EDGE program shows high sustained virologic responses
Subscribe for More Information
April 23, 2015
16:39 EDTMRKACETO subsidiary to launch Timolol Maleate Ophthalmic Solution
Subscribe for More Information
05:40 EDTMRKMerck announces results from C-SURFER Phase 2/3 study
Subscribe for More Information
April 22, 2015
08:18 EDTMRKOrganovo enters into a collaboration agreement with Merck Sharp and Dohme
Subscribe for More Information
1 | 2 | all recent MRK news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use